Amid the increasing cases of coronavirus in India, the expert committee has recommended the use of Russian vaccine Sputnik V in India. If approved by regulator DCGI, it will become India’s third vaccine against the covid-19 infection after Covishield and Covaxin.
Dr Reddy’s had tied up with Russian Direct Investment Fund (RDF) to produce the vaccine doses for emergency use of Sputnik V.
Currently, its trials are going on in India, on around 1,600 people aged between 18 and 99. The vaccine is also in trials in the UAE, Venezuela and Belarus.
The sources also informed that “Sputnik is expected to be available latest by June” and it will provide a big boost in the war against Covid-19, with a production capacity of 850 million doses in the country.
The two-dose vaccine, developed by Russia’s Gamaleya Institute, costs less than $10 for each shot in international markets. The dry form of the vaccine can be stored at 2 to 8 degrees.
Yesterday, top government sources has also revealed that India is soon going to expect four more vaccines apart from Sputnik V which are – Johnson & Johnson vaccine (in collaboration with Biological E), Novavax vaccine (in collaboration with Serum India), Zydus Cadila’s vaccine, and Bharat Biotech’s Intranasal Vaccine.
The government is taking all steps to augment vaccine production and availability in India. A decision has been taken at the highest level to ensure all steps are taken to help domestic manufacturers to scale up vaccine production manifold.